The aim of the current study was to elucidate the clustering pattern of metabolic syndrome components along with apolipoproteins (Apo) A-I and B in diabetic and nondiabetic subjects.
Methods:
Factor analysis of conventional variables of metabolic syndrome [i.e., waist circumference, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), and systolic blood pressure (SBP)] with or without addition of Apo A-I and B was performed on 567 and 327 diabetic and nondiabetic subjects, respectively. Thereafter, analyses were repeated after substitution of TG and HDL-C by the TG-to-HDL-C ratio (TG/HDL-C).
Results:
Regarding conventional variables of metabolic syndrome, one or two underlying factors were identified, depending on whether lipid measures were entered as two distinct variables or as a composite measure. Apolipoproteins were consistent with a one-factor structure model of metabolic syndrome and did not change the loading pattern remarkably in nondiabetics. TG and HDL-C tended to cluster with Apo B and A-I, respectively, in different models.
Conclusion:
The current study confirms that addition of Apo A-I and B is consistent with the one-factor model of metabolic syndrome and does not modify the loading pattern remarkably in nondiabetic subjects.
Get full access to this article
View all access options for this article.
References
1.
GrundySM, HansenB, SmithSCJret al.Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation, 2004; 109:551–556.
2.
SnidermanAD, FarajM. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol, 2007; 18:633–637.
3.
WalldiusG, JungnerI. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med, 2006; 259:493–519.
4.
MarcovinaS, PackardCJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med, 2006; 259:437–446.
5.
DavidsonMH. Apolipoprotein measurements: Is more widespread use clinically indicated?Clin Cardiol, 2009; 32:482–486.
6.
MeigsJB. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol, 2000; 152:908–911.
7.
HansonRL, ImperatoreG, BennettPHet al.Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes, 2002; 51:3120–3127.
8.
EsteghamatiA, ZandiehA, KhalilzadehOet al.Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: An exploratory factor analysis. Endocrine, 2010; 38:206–213.
9.
EsteghamatiA, ZandiehA, KhalilzadehOet al.Clustering of metabolic syndrome components in a Middle Eastern diabetic and non-diabetic population. Diabetol Metab Syndr, 2010; 2:36.
10.
KrajaAT, ProvinceMA, ArnettDet al.Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster?Nutr Metab (Lond), 2007; 4:28.
11.
LafortunaCL, AdorniF, AgostiFet al.Factor analysis of metabolic syndrome components in obese women. Nutr Metab Cardiovasc Dis, 2008; 18:233–241.
12.
SakkinenPA, WahlP, CushmanMet al.Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol, 2000; 152:897–907.
13.
MatthewsDR, HoskerJP, RudenskiASet al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
14.
GenuthS, AlbertiKG, BennettPet al.Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26:3160–3167.
15.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [article online]2006. www.idf.org/webdata/docs/IDF_Meta_def_final.pdf/. 2012 March 14.
16.
HodgeAM, BoykoEJ, de CourtenMet al.Leptin and other components of the Metabolic Syndrome in Mauritius—a factor analysis. Int J Obes Relat Metab Disord, 2001; 25:126–131.
17.
LeyvaF, GodslandIF, GhateiMet al.Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol, 1998; 18:928–933.
18.
PyoralaM, MiettinenH, HalonenPet al.Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol, 2000; 20:538–544.
19.
LawlorDA, EbrahimS, MayMet al.(Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol, 2004; 159:1013–1018.
20.
WallenfeldtK, BokemarkL, WikstrandJet al.Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke, 2004; 35:2248–2252.
21.
Sierra-JohnsonJ, Romero-CorralA, SomersVKet al.ApoB/apoA-I ratio: An independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J, 2007; 28:2637–2643.
22.
Sierra-JohnsonJ, SomersVK, KuniyoshiFHet al.Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol, 2006; 98:1369–1373.
23.
BelfkiH, Ben AliS, BougatefSet al.The apolipoprotein B/apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp Mol Pathol, 91:622–625.
24.
MattssonN, MagnussenCG, RonnemaaTet al.Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: The cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol, 2010; 30:1861–1866.
25.
SungKC, HwangST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis, 2005; 180:161–169.
26.
HanJH, ParkHS, KimJAet al.Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans. Atherosclerosis, 2008; 197:333–338.
27.
SattarN, WilliamsK, SnidermanADet al.Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation, 2004; 110:2687–2693.
28.
WilliamsK, SnidermanAD, SattarNet al.Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)Circulation, 2003; 108:2312–2316.
29.
LaaksonenDE, NiskanenL, NyyssonenKet al.Dyslipidaemia as a predictor of hypertension in middle-aged men. Eur Heart J, 2008; 29:2561–2568.
30.
ShmulewitzD, AuerbachSB, LehnerTet al.Epidemiology and factor analysis of obesity, type II diabetes, hypertension, and dyslipidemia (syndrome X) on the Island of Kosrae, Federated States of Micronesia. Hum Hered, 2001; 51:8–19.
